Genetic precision medicine

The project aims to identify, characterize and quantify the hitherto unexplained genetically-predicted inter-individual variability in drug response which will enable the clinicians to perform precise dosing for each individual patient.

Three different labs with complementary competence and extensive experience in the field will utilize the data on plasma concentrations, treatment failure, adverse drug reactions, alongside with DNA sequences which will be obtained from biobanked and prospective DNA derived from highly powered patient cohorts treated with frequently-prescribed psychiatric drugs, in total data from > 20,000 patients.

Special emphasis will be placed on the identification of i) novel haplotypes related to altered drug response, ii) contribution of globally identified mutations of importance for adverse drug reactions response, iii) the role of rare mutations and iv) the development of a novel genetic platform to be used in genetic precision medicine.

The project aims to deliver a novel diagnostic tool, in compliance with the FAIR principles and GDPR, to be implemented for decision support by integrating AI-derived pharmacogenomics-based algorithms into existing electronic infrastructure.

Such a treatment individualization would significantly improve pharmacotherapy both in primary and secondary health care.